Key result
Chronic ACE inhibitor treatment in hypertensive patients was associated with significantly higher plasma Ac-SDKP levels compared to no ACE inhibitor treatment (3.78 vs 0.75 pmol/mL; P<.0001).
Why the study?
Does chronic ACE inhibitor treatment increase plasma levels of Ac-SDKP in hypertensive patients?
Observational (n=50)
Blinded outcome assessment
Does chronic ACE inhibitor treatment increase plasma levels of Ac-SDKP in hypertensive patients?
Absolute Event Rate: 3.78% vs 0.75%
p-value: p=<.0001
Plasma Ac-SDKP measurement is a highly reliable marker of chronic ACE inhibition that can perfectly discriminate treated from untreated patients, aiding in compliance verification.
No takes yet. Share an insight, caveat, or question.
Ac-SDKP measurement may verify ACE inhibitor compliance in hypertension; supports biomarker utility but leaves open prospective validation.
Azizi et al. (1997) conducted an observational in Hypertension (n=50). ACE inhibitor treatment vs. No ACE inhibitor treatment was evaluated on Plasma Ac-SDKP levels (pmol/mL) (p=<.0001). Chronic ACE inhibitor treatment in hypertensive patients was associated with significantly higher plasma Ac-SDKP levels compared to no ACE inhibitor treatment (3.78 vs 0.75 pmol/mL; P<.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: